The chart serves its purpose as a general reminder of each product and where its up to. Not sure about the data for SubB2M prostate cancer or whether they have got that far. BD1's primary focus has been on Breast and Ovarian cancers, with Pancreatic, Prostate and Lung cancers to follow.
I found a great article from Alan Kohler who interviewed our CEO Dr Leearne Hinch below - great insight and worth a read!
Link can't be added - search "eureka report BARD1 life sciences australian biotech success story" and it should come up.
